{"id":"W4415939974","doi":"10.1016/j.annonc.2025.08.720","title":"291O DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"Jewish General Hospital; AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Pertuzumab; Trastuzumab; Paclitaxel; Breast cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005176446,0.000601517,0.001291096,0.0002961473,0.000212972,0.0008772602,0.0004714057,0.0007424838,0.008541778],"category_scores_gemma":[0.0006264491,0.0002576529,0.001006829,0.0002397152,0.0006254123,0.0008077291,0.000362509,0.001485466,0.0008791416],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006471272,"about_ca_system_score_gemma":0.001138585,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001343881,"about_ca_topic_score_gemma":0.004620237,"domain_scores_codex":[0.9997997,0.00006131535,0.00001396928,0.00003630376,0.00001807264,0.00007069048],"domain_scores_gemma":[0.9996793,0.00008866283,0.00003570389,0.00002963088,0.0000113971,0.0001552278],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8796234,0.01666082,0.002885267,0.0005330391,0.000672052,0.0001336606,0.0001029213,0.001420934,0.01493248,0.0006964119,0.003584936,0.07875403],"study_design_scores_gemma":[0.3157194,0.6234735,0.0262115,0.0002879275,0.002251405,0.0006444884,0.0003352347,0.003490036,0.01190031,0.001217826,0.0143804,0.00008799464],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990557,0.002259743,0.0001862647,0.0007303807,0.0006199967,0.0002750678,0.0007218645,0.00003834008,0.004611405],"genre_scores_gemma":[0.9900147,0.002310397,0.0006145703,0.000632126,0.0003021947,0.0002762571,0.001465131,0.0000234558,0.00436111],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008541778,"threshold_uncertainty_score":0.02857512,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06240779686711495,"score_gpt":0.4212785404278276,"score_spread":0.3588707435607127,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}